

Special Issue

Heterogeneity of Neuroendocrine Tumors: Impact on Biology and Response to Treatments

Message from the Guest Editors

Recent advances in the understanding of NEN biology have resulted in a rising number of available treatments, including surgery, somatostatin analogs, chemotherapy, targeted therapies, liver-directed therapies, and peptide receptor radionuclide therapy. However, most of these treatments are used based on a low level of evidence, and comparisons between them have been scarce. In particular, the impact of the heterogeneity of NEN on treatment efficacy has been poorly explored. Because factors predictive of treatment efficacy are lacking, therapeutic decision-making is essentially influenced by prognostic factors. This Special Issue aims to gather cutting-edge research on the characterization and therapeutic advances in NEN, with a focus on the impact of their heterogeneity on tumor biology and treatment efficacy. Original research and review articles should present new data from basic or clinical research and/or provide an innovative and critical appraisal of previous research. Papers exploring novel clinical or molecular biomarkers impacting prognosis and treatment efficacy are particularly welcome.

Guest Editors

Dr. Louis de Mestier
Beaujon Hospital, Université de Paris, Paris, France

Prof. Jérôme Cros
Beaujon Hospital, Université de Paris, France

Deadline for manuscript submissions

closed (31 August 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/64428

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)